FiercePharmaAsia—Novartis’ kickback allegation, Samsung’s Humira biosim, Takeda’s Shire plan
admin 13th April 2018 Uncategorised 0Novartis is facing allegations in China that it laundered doctor kickbacks through fake academic events, Samsung Bioepis has pushed back the U.S. launch of its Humira biosimilar by years, Takeda is seeking billions of dollars in loans to finance its Shire bid, and more.
More: FiercePharmaAsia—Novartis’ kickback allegation, Samsung’s Humira biosim, Takeda’s Shire plan
Source: fierce